疾病修飾療法

疾病修飾治療、疾病修飾藥物或疾病修飾療法是一種通過針對疾病的根本原因來延緩、減緩或逆轉疾病進展的治療方法。 ^[1]它們不同於對症治療，對症治療只治療疾病的症狀，而不解決其根本原因。 ^[2]（修飾一詞的翻譯可能來自於生物學術語：生物學中的修飾是指對蛋白質分子的結構或功能進行化學修飾，以改變其生物學性質的一種生物化學過程）

例子

骨關節炎的疾病修飾藥物^[3]
抗風濕的疾病修飾藥物^[4]
疾病修飾療法用於治療阿爾茲海默症^[5]、帕金森症^[6]

參考文獻

^ McFarthing, Kevin; Rafaloff, Gary; Baptista, Marco; Mursaleen, Leah; Fuest, Rosie; Wyse, Richard K.; Stott, Simon R.W. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update. Journal of Parkinson's Disease. 2022-05-24, 12 (4): 1073–1082. PMC 9198738  . PMID 35527571. doi:10.3233/JPD-229002.
^ Symptomatic Versus Disease-Modifying Therapies for Movement Disorders - Parkinson's and Movement Disorder Foundation. pmdf.org. [2022-09-11]. （原始內容存檔於2024-04-10）.
^ Disease-modifying osteoarthritis drug. Wikipedia. 2023-08-29 （英語）.
^ Disease-modifying antirheumatic drug. Wikipedia. 2024-02-15 （英語）.
^ Munoz-Torrero, D. Acetylcholinesterase Inhibitors as Disease-Modifying Therapies for Alzheimer's Disease. Current Medicinal Chemistry. 2008-10-01, 15 (24) [2024-04-10]. doi:10.2174/092986708785909067. （原始內容存檔於2024-04-12）.
^ AlDakheel, Amaal; Kalia, Lorraine V.; Lang, Anthony E. Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease. Neurotherapeutics. 2014-01-01, 11 (1) [2024-04-10]. ISSN 1878-7479. doi:10.1007/s13311-013-0218-1. （原始內容存檔於2024-04-26）.

[1] McFarthing, Kevin; Rafaloff, Gary; Baptista, Marco; Mursaleen, Leah; Fuest, Rosie; Wyse, Richard K.; Stott, Simon R.W. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update. Journal of Parkinson's Disease. 2022-05-24, 12 (4): 1073–1082. PMC 9198738  . PMID 35527571. doi:10.3233/JPD-229002.

[2] Symptomatic Versus Disease-Modifying Therapies for Movement Disorders - Parkinson's and Movement Disorder Foundation. pmdf.org. [2022-09-11]. （原始內容存檔於2024-04-10）.

[3] Disease-modifying osteoarthritis drug. Wikipedia. 2023-08-29 （英語）.

[4] Disease-modifying antirheumatic drug. Wikipedia. 2024-02-15 （英語）.

[5] Munoz-Torrero, D. Acetylcholinesterase Inhibitors as Disease-Modifying Therapies for Alzheimer's Disease. Current Medicinal Chemistry. 2008-10-01, 15 (24) [2024-04-10]. doi:10.2174/092986708785909067. （原始內容存檔於2024-04-12）.

[6] AlDakheel, Amaal; Kalia, Lorraine V.; Lang, Anthony E. Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease. Neurotherapeutics. 2014-01-01, 11 (1) [2024-04-10]. ISSN 1878-7479. doi:10.1007/s13311-013-0218-1. （原始內容存檔於2024-04-26）.

[1]

[2]

[3]

[4]

[5]

[6]